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Abstract
As an atypical member of cyclin dependent kinase family, Cyclin dependent kinase 5 (Cdk5) is considered as a neuron-
specific kinase in the past decade due to the abundant existence of its activator p35 in post-mitotic neurons. Recent
studies show that Cdk5 participates in a series of biological and pathological processes in non-neuronal cells, and is
generally dysregulated in various cancer cells. The inhibition or knockdown of Cdk5 has been proven to play an anti-
cancer role through various mechanisms, and can synergize the killing effect of chemotherapeutics. DNA damage
response (DDR) is a series of regulatory events including DNA damage, cell-cycle arrest, regulation of DNA replication,
and repair or bypass of DNA damage to ensure the maintenance of genomic stability and cell viability. Here we
describe the regulatory mechanisms of Cdk5, its controversial roles in apoptosis and focus on its links to DDR and
cancer.
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Background
Cyclin dependent kinases (Cdks) are a large family of
serine/threonine kinases, consisting of 20 Cdks (Cdk1-
Cdk20) and 5 Cdk-like (Cdkl) proteins (Cdkl1-Cdkl5),
numbered by their discoveries [1]. Cyclin dependent kin-
ase 5 (Cdk5) is a member of Cdk family which share a
basic structure and high conserved sequence, with the
catalytic site that binds to ATP sandwiched between
N- and C-terminal lobes [2]. Unlike other Cdks, Cdk5
generally neither participates in the regulatory pro-
gression of cell cycle control nor is activated by
cyclins, but is activated by binding with non-cyclin
Cdk5 activators Cdk5R1 (p35) and Cdk5R2 (p39), or
their respective truncations p25 and p29, all of which
are originally found abundant in post-mitotic neurons.
The predominant distribution of Cdk5 activators in
neurons makes Cdk5 a neuron-specific Cdk [3].
Over the last decade Cdk5 has been proven to play a
critical role in essential neuronal functions, including con-
trol of cytoskeletal architecture and dynamics, axonal
guidance, neuronal migration, cell adhesion, etc.; and par-
ticipate in the pathological changes in neurodegenerative
diseases [4]. However, there is growing evidence of its
roles outside the nervous system. Cdk5 has been found to
participate in several biological processes of extraneuronal
activities, such as gene expression, cell migration, apop-
tosis, myogenesis, etc.; and pathological processes includ-
ing cancer, senescence, diabetes, immune dysfunction and
inflammation [5, 6]. Cdk5 is generally dysregulated in vari-
ous types of cancer and is linked with cancerous charac-
teristics and prognoses [6], making it a novel biomarker
and promising therapeutic target in cancer treatment.
Recent studies have also shown that the disruption of
DNA damage response (DDR) plays an important role in
cancer development and treatment [7]. The basic function
of DDR is to repair the DNA damage and keep the integ-
rity and stability of genome, which is related to tumori-
genesis and progression. DDR includes the event of DNA
repair process itself and other events such as the detection
of DNA lesions, cell-cycle arrest, etc. [8, 9]. Pearl and his
colleges have compiled a data set of 450 genes encoding
proteins that are integral to the DDR [10], revealing their
roles and therapeutic potentials in cancer and treatment.
Cdk5 takes part in DDR process mainly by phosphorylat-
ing some of the critical DDR proteins such as ataxia–tel-
angiectasia mutated (ATM) and apurinic/apyrimidinic
endonuclease 1 (Ape1), and the inhibition of this kinase
activity has been proven to regulate DDR process and
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cancer progression [11, 12]. Here we focus on the regula-
tion of Cdk5, its dual roles in apoptosis, and its links with
DDR and cancer development and treatment. To our best
known, this would be the first review that elaborates the
roles of Cdk5 in DDR and its links with cancer
characteristics.
Regulation of Cdk5
The regulatory mechanism of Cdk5 is well elucidated in
neurons. Cdk5 itself does not own an enzymatic activity.
Physiologically Cdk5 is activated by binding with p35,
and the complex of Cdk5/p35 is predominantly cytoplas-
mic and membrane-associated due to myristoylation of
p35 [13]. p35 is a short-lived protein with a life span of
20-30mins, which can be phosphorylated by activated
Cdk5 [14], leading to its ubiquitination and degradation
by proteasome [15]. Its degradation by proteasome re-
sults in an attenuated activity of Cdk5 and forms a
negative-feedback modulation of Cdk5 activity [16–18].
When cell faces cell death signals, the N-methyl-D-as-
partate receptor (NMDAR) on cellular membrane is ac-
tivated and membrane permeability to calcium is
increased, which subsequently activates calpain protein.
Calpain owns a proteolytic activity which cleaves p35
into p25 fragment, a much more stable protein than
p35. The cleavage results in a translocation of Cdk5/p25
complex into nucleus and prolonged activation of Cdk5,
which induces pathological signaling pathways of cell
death [19, 20] [Fig. 1]. Both calpastatin and calpeptin, an
endogenous and an exogenous calpain-inhibitor respect-
ively, can attenuate Cdk5 activity by suppressing the
cleavage of p35 into p25 [21, 22]. Similarly, p39 can also
be cleaved into a more stable subunit p29, which results
in Cdk5 hyperactivation and relocation [23]. Yet the
function and significance of p29 remain to be
characterized.
Since Cdk5 plays its enzymatic activity through its ac-
tive form Cdk-p35/Cdk-p25 complex, the activation of
Cdk5 is mainly regulated by the regulation of Cdk5 acti-
vator p35/p25. It has been reported that the binding of
transcription factors such as early growth response gene
1 (Egr1), POU-homeodomain transcription factors
Pou3f3 (Brn1) and Pou3f2 (Brn2) to the promoter of p35
gene can positively regulate p35 mRNA expression and
Mitogen-activated protein kinase (MAPK) signaling
dependent up-regulation of p35 in neuronal and non-
neuronal cells, resulting in enhanced enzyme activity of
Cdk5 [24, 25]. Cdk5 kinase activity can also be regulated
through post transcriptional modulation of p35 mRNA.
The long 3’ untranslated region (UTR) of p35 mRNA,
which contains putative GY box motif and AU-rich ele-
ments, has been reported to affect mRNA stability in
neuronal and non-neuronal cells [26]. The binding of
neuron-specific embryonic lethal abnormal vision
(nELAV) to p35 mRNA 3’-UTR can positively control
p35 mRNA stability, while heterogeneous nuclear ribo-
nucleoproteins A2/B1 (hnRNPA2/B1), miR-103 and
miR-107 miRNAs are reported to have a negative effect
on p35 mRNA stability [27, 28]. Besides, post-
translational modifications of p35 protein, such as
sumoylation and S-nitrosylation, can respectively in-
crease and restrain Cdk5 activity [29, 30]. Furthermore,
the over-expression of two small peptides derived as
truncations of p35, Cdk5 inhibitory peptide (CIp) and
peptide 5 (p5), can selectively inhibit hyperactivation of
Cdk5/p25 without affecting endogenous Cdk5/p35 activ-
ity [31, 32] [Fig. 2].
Apart from the canonical Cdk5 activators p35 and
p39, recent studies have identified more factors that can
regulate Cdk5 activity. Cdk5 activity can be restricted by
its interaction with cyclin E, which can further influence
synaptic plasticity and memory formation in neurons
[33]. Cyclin D1 over-expression results in attenuated
Cdk5/p35 activity, probably by its competition with p35
for Cdk5 in cortical neuronal cell [34]. Cyclin G1 is re-
ported to activate Cdk5 in lung and colorectal cancer
cells by protein interaction [35]. Glutathione-S-
transferase pi 1 (GSTP1) is demonstrated to inhibit
Cdk5 activity directly by binding to Cdk5 and dislodging
p25/p35, and indirectly by suppressing oxidative stress-
induced Cdk5 hyperactivation in neuronal and cancer
cells [36]. Nestin, an intermediate filament protein, can
bind with Cdk5/p35 complex and create sequestration
which depresses p35 processing, resulting in attenuated
Cdk5-p25 activation and subsequent restriction of myo-
blast differentiation [37].
Cdk5’s dual roles in apoptosis
Studies have shown that Cdk5 plays a protective role in
cell survival. In INS 832/13 and primary β-cells, the
knockdown of Cdk5 or p35 leads to a significant de-
crease in focal adhesion kinase (Fak) activity and its
downstream phosphorylation of Akt at ser473, which is
known as a protective factor of cell survival; and an ob-
vious increase in caspase-3 cleavages, which is a symbol
of apoptosis [38]. The anti-apoptosis role of Cdk5 has
also been proved in thyroid cancer cells [39] and pros-
tate cancer cells [40].
However, there is also enough evidence revealing its
roles of pro-apoptosis in various cells. In neurons, Cdk5
activation can mediate an aberrant S-phase entry and
death of cells by different signaling pathways, including
inhibition of Cdh1-mediated activation of anaphase-
promoting complex/cyclosome (APC/C) [41]; phosphor-
ylation of C-terminus of Hsc70-interacting protein
(CHIP) [42], myocyte enhancer factor 2D (MEF2D) [43],
and NMDAR subunit 2A (NR2A) [44]; and remodeling
of chromatin structure [45]. In prostate cancer cells
Liu et al. Molecular Cancer  (2017) 16:60 Page 2 of 9
exposed to retinoic acid (RA) treatment (a traditional
anti-cancer drug), Cdk5 is overactivated and cell prolif-
eration is suppressed. Both the inhibition and knock-
down of Cdk5 can obstruct RA-triggered apoptosis and
caspase 3 activation [22]. Cdk5 is also proved to be an
apoptosis-enhancing signal in ischemic injury. Cdk5
mediates ischemia-induced cell death through phosphor-
ylation and inactivation of peroxiredoxin 2 (Prx2) and
MEF2D, an antioxidant enzyme and an survival promoting
transcription factor respectively. Moreover, the treatment
with Cdk5 inhibitors can suppress the ischemia-induced
cell death in renal tubular cells, suggesting the potential
value of Cdk5 for ischemia-relating diseases and renal
preservation [46, 47].
Involvement of Cdk5 in DDR
Cells are challenged by tens of thousands of lesions on
their DNA everyday, which vary from creating DNA
crosslinks to block DNA replication to causing DNA
double-strand breaks (DSBs) to damage genome integ-
rity. If unrepaired or aberrantly repaired, these DNA
damages can be accumulated and commit cells to apop-
tosis or induce aberrant cellular signaling pathways lead-
ing to cancer [48]. Thus cells have developed a
sophisticated net of regulatory pathways collectively
termed DNA damage response. The principle of DDR is
to ensure the lesions of DNA damage are well-repaired
before the genetic materials are inherited to progeny.
The events contain the detection of DNA damage, cell-
cycle arrest, regulation of DNA replication, and repair or
bypass of DNA damage to ensure the maintenance of
genomic stability and cell viability [49]. DDR has been
elucidated to be linked with tumorigenesis and treat-
ment and drug-resistance of tumor [50]. Here we focus
on the roles of Cdk5 in DDR through different
pathways.
As a widely proline directed serine/threonine protein
kinase, Cdk5 is not directly involved in DNA repair, but
regulates DDR by phosphorylating various key regulators
of DDR process. At least 450 proteins integral to DDR
have been analyzed, and one of these DDR proteins is
Ape1, which is essential in the base excision repair
(BER) pathway, one of the key repair mechanisms for
DNA damage [50]. Ape1 can cleave apurinic/apyrimidi-
nic (AP) site caused by DNA damage, and facilitate the
following repair processes of BER by subsequent
enzymes [51]. Huang and his collegues demonstrated
that in neurons Cdk5 is hyperactivated and Ape1 is
Fig. 1 The regulatory mechanism of Cdk5 in neurons. Cdk5 itself does not own an enzymatic activity. Physiologically Cdk5 is activated by binding
with p35 and the complex of Cdk5/p35 is concomitantly recruited to membrane via the myristoylation of p35. p35 is a short-lived protein which
is soon degraded by proteasome, resulting in transient activation of Cdk5. When cell faces cell death signals, the NMDAR on cellular membrane is
activated and membrane permeability to calcium is increased, leading to activation of calpain protein. Activated Calpain cleaves p35 into p25
fragment, a much more stable protein than p35, resulting in translocation of Cdk5/p25 complex into nucleus and prolonged activation of Cdk5,
which induces pathological signaling pathways of cell death
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phosphorylated at Thr 232 upon oxidative stress and DNA
damage [11]. The phosphorylation of Ape1 leads to signifi-
cantly attenuated AP endonuclease activity and failure of
DNA damage repair. Inhibition of Cdk5 can dephosphory-
late Ape1 and rescue the AP endonuclease activity of Ape1
and contribute to DNA damage repair [11], suggesting that
the hyperactivation of Cdk5 promotes DNA damage
process through phosphorylation of Ape1 and subsequent
inactivation of AP endonuclease activity, and the inhibition
of Cdk5 facilitates DNA damage repair.
Cdk5 also influence the DDR process by regulating the
signal transducer and activator of transcription 3
(STAT3)-mediated up-regulation of essential meiotic
structure-specific endonuclease 1 (Eme1), an endonucle-
ase that is implicated in rescuing broken replication
forks in response to DNA damaging agents [52, 53].
STAT3 proteins are cytoplasmic transcription factors
that translocate to the nucleus and induce cell cycle
progression in response to growth factor stimulation
[54]. In growing cancer cells, the constitutive activation
of STAT3 via JAK-mediated phosphorylation on tyrosine
705 allows the nuclear translocation and DNA binding
of STAT3 and up-regulation of several genes such as
cyclin D1 gene and myc gene, two kinds of proliferative
genes, leading to cell cycle activation and proliferation.
When cells are treated with topoisomerase I inhibitor (a
DNA damaging agent), the activation of STAT3 by JAK
is inhibited, leading to decreased expression of cyclin D1
and myc. However, both the expression and activity of
Cdk5 are increased in response to DNA damaging agent,
and co-immunoprecipitation and pulldown experiments
show that up-regulated Cdk5 associates with STAT3 and
promotes phosphorylation of STAT3 on serine 727 and
subsequent activation of STAT3. The activated STAT3
then translocates to nucleus and interacts with the pro-
moter of Eme1 gene, promoting the rescue of broken
Fig. 2 The activation of Cdk5 is regulated by modulation of p35 in different levels. In transcriptional level, the transcription factors Egr1, Brn-1 and Brn-2
can bind to the promoter of p35 gene and positively regulate its mRNA expression. After transcription, the binding of nELAV to p35 mRNA 3’-UTR can
positively control its mRNA stability, while hnRNPA2/B1, miR-103 and miR-107 have a negative effect resulting in mRNA destabilization. Post-translational
protein modifications of p35, sumoylation and S-nitrosylation, can respectively increase and restrain Cdk5 activity. The over-expression of two small peptides
derived as truncations of p35, CIp and p5, can selectively inhibit Cdk5/p25 hyper-activation without affecting endogenous Cdk5/p35 activity
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replication forks caused by DNA damage. The inhibition
of Cdk5 can inhibit the STAT3-mediated up-regulation
of Eme1 and result in impaired DNA repair and in-
creased DNA damage and further decreased cell viability
[52] [Fig. 3]. Taken all together, the up-regulation of
Cdk5 is a result of DNA damage stimulation and in turn in-
duces DNA repair through STAT3-mediated up-expression
of Eme1, which may confer cancer cells resistance to
chemotherapy treatment.
The roles of Cdk5 in DNA damage repair have also
been reported to be mediated by interaction with ATM
kinase, a crucial regulator in DDR process [55]. ATM is
demonstrated to favor homologous recombination (HR)
after being recruited to DSBs by MRE11-RAD50-NBS1
(MRN) complex [56]. ATM is involved in presynapsis of
HR by recruiting and activating nuclease enzymes
including BRCA1, CtIP, EXO1 and BLM, which resect
DSB ends to generate 3’-ssDNA overhangs and hence
facilitate RAD51 nucleofilament formation [57, 58]. Be-
sides, recent study shows ATM is additionally engaged
in the later steps of HR after DSB end resection and
RAD51 loading [59]. Cdk5 is proved to be responsible
for ATM activation by promoting the phosphorylation of
ATM at Ser 794 and subsequent autophosphorylation,
and mediate DNA damage signaling, cell cycle check-
point and neuronal death in post-mitotic neurons [12].
There are also reports that Cdk5 play a role in DDR by
phosphorylating Prx2 (an antioxidative enzyme) [60],
P53 (a tumor suppressor protein) [61] and p19INK4d (a
member of cell cycle inhibitor family INK4) [62],
whereas the signaling pathways need further exploration
and elucidation.
Fig. 3 Cdk5 takes part in DDR through STAT3 pathway. In growing cancer cells, the constitutive activation of STAT3 via JAK-mediated phosphorylation on
tyrosine 705 allows the nuclear translocation and DNA binding of STAT3 and up-regulation of cyclin D1 gene and myc gene, leading to cell cycle activation
and proliferation. When cells are treated with topoisomerase I inhibitor (a DNA damaging agent), the activation of STAT3 by JAK is inhibited, while the
expression and activity of Cdk5 are increased in response to DNA damaging agent. Up-regulated Cdk5 associates with STAT3 and phosphorylates it on
serine 727, leading to activation of STAT3. The activated STAT3 then translocates to nucleus and interacts with the promoter of Eme1 gene, promoting the
rescue of broken replication forks caused by DNA damage
Liu et al. Molecular Cancer  (2017) 16:60 Page 5 of 9
Cdk5 links with cancer
Tumorigenesis is a series of complex processes, with a
variety of aberrant signaling changes which confer cells
cancerous characteristics. Surgery therapy is no more
the only way for cancer treatment, looking for the
potential biomarkers and effective target therapies has
become the current hotspot [63]. The emerging know-
ledge of the roles of Cdk5 in cancer indicates that it is a
potential biomarker for diagnosis and prognosis predic-
tion for cancer. Cdk5 is reported to be over-expressed or
hyperactivated in various cancer tissues and tumor cell
lines. In patients with lung cancer it is associated with
clinical pathological characteristics and poorer progno-
ses [64]. In head and neck squamous cell carcinoma,
aberrant over-expression of Cdk5 significantly induces
tumor cell motility and epithelial mesenchymal transi-
tion (EMT), which is considered as a pivotal process of
cancer metastasis [65]. In hepatocelluar carcinoma (HCC),
over-expression and hyperactivation of Cdk5 play an
oncogenic activity by inducing proliferation and clono-
genic growth of HCC [66]. In pancreatic cancer cells,
Cdk5 is widely active. Blockade of Cdk5 can remarkably
downregulate the two active forms of Ral proteins RalA-
GTP and RalB-GTP, and Rho-GTP and Rac-GTP levels,
all of which play an important role in oncogenic Ras-
induced neoplasia, tumor progression and metastasis, re-
vealing the important roles of Cdk5 in cancer progression
[67]. The roles of Cdk5 in pancreatic cancer formation
and progression via Ras-Ral signaling have been further
proven by rescue test, in which constitutively activating
RalA-GTP and RalB-GTP in pancreatic cancer cells ex-
pressing dominant-negative Cdk5 significantly rescued the
effects of Cdk5 inhibition [67]. In prostate cancer cells,
Cdk5 promotes cell growth in an androgen receptor (AR)-
independent way and maintains high AKT kinase activity,
which is known to correlate with prostate cancer progres-
sion and considered as a critical growth-promoting path-
way in prostate cancer cells [68]. There are also reports
that Cdk5 mediates prostate cancer progression through
STAT3 and AR signaling [69]. In breast cancer cells
treated with transforming growth factor beta 1 (TGF-β1,
an EMT inducer), both p35 and Cdk5 are up-regulated
and hyperactivated, leading to subsequent EMT and can-
cer cell motility by phosphorylating Fak, which is known
to be involved in cellular adhesion and spreading pro-
cesses [70]. Our work also shows Cdk5 and p35 are
significantly increased in clinical breast cancer tissues and
in breast cancer cell lines exposed to paclitaxel at tran-
scriptional and translational levels.
Though Cdk5 is generally up-regulated in most types
of cancer, it has also been reported down-regulated in
certain types of cancer. For example, in human gastric
cancer tissues, the mRNA level and protein level of
Cdk5 and p35 are both significantly reduced, and the
down-regulation is linked with poorer prognoses [71].
Cellular experiments show a lack of Cdk5 in nucleus in
different gastric cancer cell lines, but presence of Cdk5
in both the nucleus and cytoplasm in normal gastric
epithelial cell line. NS-0011, which inhibits the trans-
location of Cdk5 from nucleus to cytoplasm, can sup-
press the proliferation and xenograft tumorigenesis of
gastric cancer cells [71]. The effects of disrupting the
localization of Cdk5 by drugs reveal a novel mechanism
to limit its pathological signalings in cancer cells [71].
Taken all together, Cdk5 participates in tumorigenesis,
progression and metastasis of different cancers through
various signaling pathways, and its inhibition and knock-
down have been proven to be effective in restraining
cancer cell progression. All the studies provide potential
targets of Cdk5-relating pathways for cancer treatment.
Implication of Cdk5 in cancer treatment
Cancer is currently the most threatening challenge
worldwide and the development of novel targeted cancer
therapy (TCT) is of utmost clinical importance. Different
from the traditional cellular toxic chemo-therapy, TCT
plays its stronger anti-cancer effect by targeting specific-
ally to the aberrant characteristics of cancer cells and
meanwhile reduces the toxic effects on normal cells [72].
Up to now a total of 30 TCT drugs have been approved
by America Food and Drug administration (FDA) since
1960s, targeting at epidermal growth factor receptor
(EGFR), hairy-related 2 (HER-2), AR signaling, Poly-(ADP-
ribose) polymerase (PARP), mammalian target of rapamy-
cin (mTOR) signaling, etc. No specific drugs that target
Cdk5 signaling have been approved, nevertheless a wave of
emerging studies reveal that Cdk5 is a promising thera-
peutic target in cancer treatment. Dinaciclib (formerly
SCH727965), a potent and selective small molecule inhibi-
tor of Cdk2, Cdk5, Cdk1 and Cdk9, is the first Cdks inhibi-
tor to enter the clinic trail. Its promising anti-cancer results
and acceptable safety profile have been respectively proven
in preclinical studies and human phase I trial. In preclinical
model of ovarian cancer, SCH727965 has been shown to
synergize with cisplatin in killing cancer cells [73]. In phase
I trial of SCH727965, subjects with advanced malignancies
experienced acceptable and tolerable dose-limiting toxic-
ities, including orthostatic hypotension, elevated uric acid,
nausea, anemia, neutropenia, etc. [74]. Besides, As Cdk5 is
hyperactivated in a degradation-dependent pathway by pro-
teasome calpain, we speculate that the proteasome inhibitor
Bortezomib (Velcade), which has been approved by FDA
for mantle cell lymphoma treatment [75], may play anti-
cancer function to some extent by regulating Cdk5-related
pathways in other cancers.
Cdk5 also plays an important role in treatment of
chemo-resistant cancers. For example, in cervical cancer
the expression of cyclin I is up-regulated by cisplatin
Liu et al. Molecular Cancer  (2017) 16:60 Page 6 of 9
treatment, which in turn confers cancer cells resistance
to cisplatin by activating Cdk5 and its anti-apoptosis ef-
fect. Knockdown of Cdk5 with siRNA can significantly
increase the sensitivity to cisplatin in Hela cell lines with
over-expressed cyclin I [76]. Similar results are also
observed in Cdk5-inhibited HCC cells [66] and Cdk5-
depleted ovarian cancer cell lines [77], in which cancer
cells exhibit higher sensitivity to DNA damaging agents.
The inhibition of Cdk5 can also reduce the side effects
of some chemo-therapy strategies. For example, Paclitaxel
is one of the widely used chemotherapeutics for various
solid tumors, while its continuous dose is reported to
induce tumor dissemination and metastasis. Both specific
inhibition and knockdown of Cdk5 are able to suppress
tumor migrational and invasive ability by impairing the
paclitaxel-induced invadopodia formation and EMT
process [78, 79]. Taken all together, Cdk5-related signal-
ings are promising targets for cancer treatment, and the
combination of Cdk5 inhibition and chemo-therapy can
synergize the killing effect and reduce side effects, provid-
ing a potential strategy for better clinical application of
chemotherapeutic agents.
Conclusion
The level of Cdk5 and its kinase activity are generally
dysregulated in various cancer tissues and tumor cell
lines, and the dysregulation is linked with DDR, apop-
tosis, tumorigenesis, EMT, metastasis and other cancer-
ous characteristics via a series of complex mechanisms.
Cdk5 is considered as a potential biomarker in different
cancers and a promising target for cancer treatment.
The inhibition of Cdk5 can effectively suppress cancer
proliferation and metastasis in cancer cells, and can
synergize the killing effect of chemotherapeutics and
meanwhile reduce its side effects, providing a better strat-
egy for the clinical application of chemotherapeutics.
However, the knowledge of the biological and pathological
functions of Cdk5 in DDR and cancer is still limited, more
efforts need to be taken to explore and exploit this kinase
better.
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